The pharmaceutical sector had it tough Thursday, falling amid poor earnings, a lost legal battle over cheap medicines and the specter of increasing competition from generic drugmakers as they lose patent protection on many blockbuster drugs.

Continue reading Pharmas Down Across the Board Amid Poor Earnings and Price Outlook

Pharmas Down Across the Board Amid Poor Earnings and Price Outlook originally appeared on DailyFinance on Thu, 22 Apr 2010 20:00:00.

Filed Under: Health Care

Roche shares climbed nearly 2% Thursday after the Swiss drugmaker posted first-quarter sales that rose 6% to 12.2 billion Swiss francs ($11.61 billion), thanks to strong demand for key cancer drugs. The results beat the average sales forecast.

Continue reading Roche Sales Grow on Cancer Drug Demand

Roche Sales Grow on Cancer Drug Demand originally appeared on DailyFinance on Thu, 15 Apr 2010 18:00:00.

Filed Under: Company News, Health Care, Earnings

For investors on the hunt for groundbreaking technologies, stem cell therapies looked promising. But while the world waited for new treatments, Wall Street lost interest. Now, the science is accelerating, but stock prices haven't caught up.

Continue reading Stem Cell Therapies: Is Now the Time to Invest?

Stem Cell Therapies: Is Now the Time to Invest? originally appeared on DailyFinance on Tue, 13 Apr 2010 14:08:00.

Filed Under: Investing, Health Care, Genzyme Corporation , Pfizer

Dendreon is developing immunologically based drugs to fight cancer, and it's No. 1 drug is Provenge, which battles prostate cancer. The excitement is about whether Provenge finally gets the FDA's approval this year. If so, the stock could keep scoring.

Continue reading Inside Wall Street: Why Hot Biotech Dendreon Could Get Even Hotter

Inside Wall Street: Why Hot Biotech Dendreon Could Get Even Hotter originally appeared on DailyFinance on Mon, 05 Apr 2010 07:30:00.

Filed Under: Technology, Columns, Investing, Health Care

We're not even halfway through March, and it seems the month has already been marked with an abundance of failed drug studies. The most recent: Three potential cancer drugs -- two from Pfizer and one from Roche -- didn't pan out in late stage clinical trials.

Continue reading Cancer Drugs from Pfizer and Roche Fail in Clinical Trials

Cancer Drugs from Pfizer and Roche Fail in Clinical Trials originally appeared on DailyFinance on Fri, 12 Mar 2010 09:41:00.

Filed Under: Company News, Healthcare, Pfizer, Astrazeneca

The following is a round-up of news likely to affect stock prices today:

National Semiconductor (NSM) reported third-quarter profit more than doubled, beating estimates. The company also predicted a 4% to 8% sequential revenue rise that was also above Wall Street's expectations. Shares climbed 1.8% ahead of the bell.

After Terra Industries' (TRA) board chose to favor a higher bid from CF Industries...

Continue reading Stocks in the News: Potash Corp, National Semi, Pacific Sunwear

Stocks in the News: Potash Corp, National Semi, Pacific Sunwear originally appeared on DailyFinance on Fri, 12 Mar 2010 07:55:00.

Filed Under: Company News, Investing, JP Morgan Chase, Pfizer, Citigroup

Roche and Biogen Idec announced Monday that they were suspending the development of Ocrelizumab for the treatment of rheumatoid arthritis following serious adverse events, including deaths, of patients in studies of the drug. They are putting the program on hold and will evaluate it before proceeding any further.

Continue reading Roche, Biogen Suspend Arthritis Drug Program After Patient Deaths

Roche, Biogen Suspend Arthritis Drug Program After Patient Deaths originally appeared on DailyFinance on Mon, 08 Mar 2010 15:00:00.

Filed Under: Company News, Healthcare

The drugmaker said that its experimental drug Recentin failed to show it was better than Roche's Avastin as a treatment for colon cancer in a late-stage, head-to-head trial. But it wasn't worse, either. Investors focused on the former and pushed AstraZeneca's stock down.

Continue reading AstraZeneca Shares Drop on Failed Colon Cancer Drug Trial

AstraZeneca Shares Drop on Failed Colon Cancer Drug Trial originally appeared on DailyFinance on Mon, 08 Mar 2010 13:41:00.

Filed Under: Company News, Healthcare, Astrazeneca

Shares of AIG are on the move Monday after the insurer agreed to sell its Alico unit to MetLife for $15.5 billion. The deal is AIG's second major asset sale this month as it attempts to whittle down its bailout tab. Click inside to see what other news is influencing Wall Street today.

Continue reading Stocks in the News: AIG, Hewlett-Packard, McDonald's

Stocks in the News: AIG, Hewlett-Packard, McDonald's originally appeared on DailyFinance on Mon, 08 Mar 2010 07:43:00.

Filed Under: Company News, Investing, Hewlett-Packard, Ford Motor Co., Kraft Foods, Apple, American International Group, INC., McDonald's, Toyota, Yahoo, Astrazeneca, MetLife

Here's a roundup of some of the major news moving stocks in the pharmaceutical industry: GlaxoSmithKline shares fell after the FDA warned against long-term use of asthma treatments Advair and Serevent. Meanwhile, a new study shows Novavax's vaccine against swine flu is effective.

Continue reading FDA Warns About Glaxo's Asthma Drug; Novavax Boosted By Vaccine Study

FDA Warns About Glaxo's Asthma Drug; Novavax Boosted By Vaccine Study originally appeared on DailyFinance on Fri, 19 Feb 2010 16:14:00.

Filed Under: Company News, Healthcare, Novavax, GlaxoSmithKline, Novartis, Astrazeneca